Inferra AI / Company / BLLN
Billiontoone, Inc.
BLLN · Health Care
Last earnings Aug 5, 2026
Key results
Total revenuequarter
$108.4 million
Financial Highlights Total revenue of $108.4 million in the first quarter of 2026, compared to $59.0 million in the first quarter of 2025, an increase of 84%.
SEC original ↗Billiontoone, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
Revenuequarter
$96.5 million
Prenatal clinical testing revenue was $96.5 million in the first quarter of 2026, an increase of 72% from the first quarter of 2025.
SEC original ↗Billiontoone, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
Oncology clinical testing revenue was $10.7 million in the first quarter of 2026, more than four times the $2.2 million reported in the first quarter of 2025.
SEC original ↗Billiontoone, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
Total revenue was $108.4 million in the first quarter of 2026 compared to $59.0 million in the first quarter of 2025, an increase of 84%.
SEC original ↗Billiontoone, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
The increase in total revenue was driven by a 44% increase in the number of total tests delivered and a 28% increase in Overall ASP.
SEC original ↗Billiontoone, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
Operating marginquarter
16%
Operating margin was 16% in the first quarter of 2026.
SEC original ↗Billiontoone, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
Net incomequarter
$18.0 million
Net income in the first quarter of 2026 was $18.0 million, or $0.34 per diluted share, compared to a net loss of $4.0 million, or $(0.39) per diluted share, in the first quarter of 2025.
SEC original ↗Billiontoone, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
AI analysis
Q1 2026 · reported May 6, 2026
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
Guidance ladder — revenue
Delivered vs the company's guided range
EX-99 · May 6, 2026 Guide as stated by the company; range and midpoint computed from the stated figure.
Headline figures
| Metric | Q1 2026 | Prior qtr | Year ago |
|---|---|---|---|
| Total revenue | $108.4 million | — | $59.0 million |
| Revenue | $96.5 million | — | — |
| Operating margin | 16% | — | — |
| Net income | $18.0 million | — | — |
Guidance · company-stated
Direction: Raised
“Raising 2026 full year revenue guidance to be in a range of $450 million to $465 million, which represents 48% to 52% growth over 2025.”
“(NASDAQ BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the first quarter ended March 31, 2026 and raised guidance for full year 2026.”
Classified from the release's primary full-year outlook statement.
Margin
Capital allocation
Cash flow from operations minus capital expenditures was $11.0 million in the first quarter of 2026.
What changed vs last quarter
- Guide midpoint vs latest-quarter revenue +315.1% computed from stated figures
Event summary
BillionToOne Reports First Quarter 2026 Results and Raises 2026 Revenue Guidance
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Raised
Revenue: “Raising 2026 full year revenue guidance to be in a range of $450 million to $465 million, which represents 48% to 52% growth over 2025.”
Revenue — Raised (“Raises”)
“htm EX-99.1 Document BillionToOne Reports First Quarter 2026 Results and Raises 2026 Revenue Guidance MENLO PARK, CA, May 6, 2026 - BillionToOne, Inc.”
Company outlook — Raised (“raised”)
“(NASDAQ BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the first quarter ended March 31, 2026 and raised guidance for full year 2026.”
Revenue — Raised (“Raising”)
“Raising 2026 full year revenue guidance to be in a range of $450 million to $465 million, which represents 48% to 52% growth over 2025.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Cash flow from operations minus capital expenditures was $11.0 million in the first quarter of 2026.
SEC original ↗Billiontoone, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
Adjusted EBITDA We define Adjusted EBITDA as net income (loss) adjusted for income taxes, interest income, interest expense, depreciation and amortization expense, and certain other items which include significant non-cash items events that are highly variable, significant in size, and that we do not believe are indicative of ongoing or future business operations, which include stock-based compensation expense change in fair value of term loan and change in fair value of warrant liabilities.
SEC original ↗Billiontoone, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
On a regular basis, management evaluates estimates, including, but not limited to: stock-based compensation, deferred tax assets and liabilities, useful lives of long-lived assets, the incremental borrowing rate applied to operating and finance leases, determination of revenue recognition and accounts receivable, and valuation of debt and common stock warrants.
SEC original ↗Billiontoone, Inc. — 10-Q Quarterly report10-QAug 5, 2026
In August 2024, the Company entered into a term loan agreement which the Company elected to account for using the fair value option.
SEC original ↗Billiontoone, Inc. — 10-Q Quarterly report10-QAug 5, 2026
As such, the fair value of the debt is calculated by using the probability weighting of the present value of settlement scenarios (See Note 7).
SEC original ↗Billiontoone, Inc. — 10-Q Quarterly report10-QAug 5, 2026
The significant assumptions used in preparing the income approach model for valuing the term loan as of June 30, 2026 and December 31, 2025, are as follows: June 30, 2026 December 31, 2025 Discount rate 6.80 % 7.10 % Annual interest rate 8.00 % 8.00 % Expected term (years) Scenario 1 3.75 4.25 Expected term (years) Scenario 2 5.1 5.6 The fair values of the Class A common stock warrants are measured using an option pricing model.
SEC original ↗Billiontoone, Inc. — 10-Q Quarterly report10-QAug 5, 2026
Strategy & priorities
We remain focused on addressing some of healthcare s most complex challenges.
SEC original ↗Billiontoone, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
These forward-looking statements generally are identified by the words believe, project, expect, anticipate, estimate, intend, strategy, future, opportunity, plan, may, should, will, would, will be, will continue, will likely result, and similar expressions.
SEC original ↗Billiontoone, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future operating results and financial position, our business strategy and plans, our market growth, and our objectives for future operations, are forward-looking statements.
SEC original ↗Billiontoone, Inc. — 10-Q Quarterly report10-QAug 5, 2026
We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial needs.
SEC original ↗Billiontoone, Inc. — 10-Q Quarterly report10-QAug 5, 2026
Risks & headwinds
We remain focused on addressing some of healthcare s most complex challenges.
SEC original ↗Billiontoone, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.
SEC original ↗Billiontoone, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
These and additional risks and uncertainties that could affect BillionToOne s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release.
SEC original ↗Billiontoone, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
These risks and uncertainties include those discussed under the captions Risk Factors and Management s Discussion and Analysis of Financial Condition and Results of Operation and elsewhere in BillionToOne s most recently filed quarterly report on Form 10-Q, the annual report on Form 10-K and other filings BillionToOne makes with the Securities and Exchange Commission from time to time.
SEC original ↗Billiontoone, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026
Legal Proceedings 43 Item 1A.
SEC original ↗Billiontoone, Inc. — 10-Q Quarterly report10-QAug 5, 2026
These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described in the section titled Risk Factors.
SEC original ↗Billiontoone, Inc. — 10-Q Quarterly report10-QAug 5, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
12 documentsEarnings releases
6 documentsPresentations
0 documentsNo presentations for Billiontoone, Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Billiontoone, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.